In addition, protein expression of survivin, a member of the inhibitor of apoptosis family whose downregulation in lapatinib-treated HER2+ breast cancer cells we had previously shown to correlate with lapatinib antitumor activity in a PI3K-dependent manner [31], remained intact in lapatinib-resistant cells. This evidence concerns the gene ERBB2 and breast cancer.